Wide Ranks

CATX

Perspective Therapeutics, Inc.

4.12

Top Statistics
Market Cap 278 M Forward PE -3.10 Revenue Growth 33.70 %
Current Ratio 9.60 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.2670 Enterprise / Revenue 9.56 Price To Sales Trailing12 Months 178.84
Profitability
Profit Margins 0.00 % Operating Margins -5049.86 %
Balance Sheet
Total Cash 267 M Total Cash Per Share 3.96 Total Debt 4 M
Total Debt To Equity 1.30 Current Ratio 9.60 Book Value Per Share 4.86
All Measures
Short Ratio 1075.00 % Message Board Id finmb_9934314 Fax 509 267 3670
Shares Short Prior Month 7 M Return On Equity -0.2702 City Seattle
Uuid a1707dc4-5cfd-3847-8a2b-6645f98c24d4 Previous Close 4.40 First Trade Date Epoch Utc 1 B
Book Value 4.86 Beta 1.47 Total Debt 4 M
Volume 2 M Price To Book 0.8474 Last Split Date 1 B
Fifty Two Week Low 2.30 Total Cash Per Share 3.96 Total Revenue 1 M
Shares Short Previous Month Date 1 B Target Median Price 18.00 Audit Risk 8
Max Age 86400 Recommendation Mean 1.30 Sand P52 Week Change 0.3133
Operating Margins -5049.86 % Target Mean Price 16.35 Net Income To Common -57712000
Ask 4.13 Short Percent Of Float 0.1490 Implied Shares Outstanding 67 M
Last Fiscal Year End 1 B Trailing Peg Ratio None Average Daily Volume10 Day 4 M
Average Volume10days 4 M Total Cash 267 M Next Fiscal Year End 1 B
Revenue Per Share 0.0290 Held Percent Insiders 0.2045 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 1
Regular Market Previous Close 4.40 Target Low Price 6.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 10.96 Open 4.60 Free Cashflow -49486876
State WA Dividend Yield 0.00 % Return On Assets -0.1435
Time Zone Short Name EST Board Risk 9 Trailing Eps -1.33
Day Low 4.12 Address1 2401 Elliott Avenue Shares Outstanding 67 M
Compensation Risk 8 Price Hint 4 Target High Price 22.50
Website https://www.perspectivetherapeutics.com 52 Week Change 0.5846 Average Volume 1 M
Forward Eps -1.08 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 952.50 % Last Split Factor 1:10 Regular Market Day High 4.64
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 1.30
Fifty Two Week High 19.10 Day High 4.64 Shares Short 8 M
Regular Market Open 4.60 Industry Key medical-devices Bid 4.13
Earnings Growth 0.00 % Enterprise To Revenue 9.56 Revenue Growth 33.70 %
Shares Percent Shares Out 0.1225 Operating Cashflow -696000 Currency USD
Time Zone Full Name America/New_York Market Cap 278 M Is_nasdaq_100 False
Zip 98121 Quote Type EQUITY Industry Medical Devices
Long Name Perspective Therapeutics, Inc. Overall Risk 7 Regular Market Day Low 4.12
Held Percent Institutions 0.8142 Current Price 4.12 Address2 Suite 320
Enterprise To Ebitda -0.2670 Financial Currency USD Current Ratio 9.60
Gross Margins 100.00 % Industry Disp Medical Devices Number Of Analyst Opinions 10
Country United States Float Shares 43 M Two Hundred Day Average 12.67
Governance Epoch Date 1 B Enterprise Value 14 M Price To Sales Trailing12 Months 178.84
Forward PE -3.10 Regular Market Volume 2 M Ebitda -55762000
Exchange ASE
Go to Yahoo Finance Go to Seeking Alpha 
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease.

The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans.

The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022.

Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.